《Effects of asiaticoside on α-actinin-4 and synaptopodin expression and ERK/JNK phosphorylation in ad》为作者：王竹最新的研究成果，本论文的主要观点为Aims: Previous studies have shown that asiaticoside exerts therapeutic effects on adriamycin-treated rats。 The aim of this study was to explore the effects of asiaticoside on adriamycin-induced expression changes in α-actinin-4 and synaptopodin, and phosphorylation changes in the extracellular signal-regulated protein kinase (ERK) and c-Jun N-terminal kinase (JNK) pathways in podocytes。 Main methods: We measured the effects of asiaticoside on podocyte viability and adriamycin-induced podocyte injury in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays。 Adriamycin (1 µmol/L) was used to establish a podocyte injury model, and western blotting was performed to detect α-actinin-4 and synaptopodin expression。 Immunofluorescence was performed to detect podocyte cytoskeletons, and western blotting facilitated the detection of ERK/JNK phosphorylation。 Key findings: Low-dose asiaticoside (10–80 μg/ml) did not affect podocyte viability, whereas high-dose asiaticoside (>80 μg/ml) decreased podocyte viability。 Adriamycin injured podocytes in vitro and decreased their viability。 Asiaticoside alleviated adriamycin-induced podocyte injury in a dose-dependent manner。 Adriamycin increased expression of the podocyte cytoskeleton protein α-actinin-4 and reduced expression of the podocyte cytoskeleton protein synaptopodin, whereas asiaticoside showed opposite effects。 Adriamycin (1 µmol/L) significantly increased ERK and JNK phosphorylation relative to that in a blank control group (p < 0。05)。 Pretreating podocytes with asiaticoside significantly inhibited adriamycin-induced ERK activation compared to that in a control group (p < 0。05); however, adriamycin-induced JNK activation was not inhibited by asiaticoside。 Significance: Pretreating podocytes with asiaticoside may reduce adriamycin-mediated injury to the cytoskeleton in podocytes and alter the protein expression levels of α-actinin-4 and synaptopodin by inhibiting adriamycin-induced activation of the ERK signaling pathway。现欲投《中药材》，不知是否符合录用要求，望您批评与指正。